Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 26, Issue 9, 1999, Pages 1890-1900

  Nagafuchi, Hiroko ^b   Suzuki, Noboru ^b   Kaneko, Atsushi ^b   Asai, Tomiaki ^b   Sakane, Tsuyoshi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Prolactin; Rheumatoid arthritis; STAT 5; Synovial cells; T lymphocytes

Indexed keywords

BROMOCRIPTINE; COLLAGENASE; CYTOKINE; MATRIX METALLOPROTEINASE; PROLACTIN; PROLACTIN RECEPTOR; STAT5 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

AGED; ARTHRITIS, RHEUMATOID; BASE SEQUENCE; BLOTTING, WESTERN; BROMOCRIPTINE; CELL DIVISION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROLACTIN; REFERENCE VALUES; SYNOVIAL MEMBRANE; T-LYMPHOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0033454104     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? [editorial]. Arthritis Rheum 1990;33:768-73.
2. Salmon M, Kitas GD, Emery P. Another interpretation of the role of T helper cells in the rheumatoid synovium. Arthritis Rheum 1989;32:795-6.
3. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997;40:598-609.
4. McInnes IB, Leung BP, Sturrock RD, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nature Med 1997;3:189-95.
5. Hedfors E. The clinical use of immunohistology. Br J Rheumatol 1989;28:278-80.
6. Soden M, Rooney M, Cullen A, Whelan A, Feighery C, Bresnihan B. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Arthritis Rheum 1989;28:287-92.
7. Martel-Pelletier J, Cloutier J-M, Pelletier J-P. In vivo effects of antirheumatic drugs on neutral collagenolytic proteases in human rheumatoid arthritis cartilage and synovium. J Rheumatol 1988;15:1198-204.
8. Reber PM. Prolactin and immunomodulation. Am J Med 1993;95:637-44.
9. Sabharwal P, Glaser R, Lafuse W, et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci USA 1992;89:7713-6.
10. Russell DH, Matrisian L, Kibler R, Larson DF, Poulos B, Magun BE. Prolactin receptors on human lymphocytes and their modulation by cyclosporin. Biochem Biophys Res Commun 1984;121:1-10.
11. DiMattia GE, Gellersen B, Bohnet HG, Friesed HG. A human B-lymphoblastoid cell line produces prolactin. Endocrinol 1988;122:2508-17.
12. Russell DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun BE. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporin. J Immunol 1985;134:3027-31.
13. Mukherjes P, Mastro AM, Hymer WC. Prolactin induction of interleukin-2 receptors on rat splenic lymphocytes. Endocrinol 1990;126:88-94.
14. Morikawa K, Oseko F, Morikawa S. Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro. Clin Exp Immunol 1993;93:200-5.
15. Morikawa K, Oseko F, Morikawa S. Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 1994;95:514-8.
16. Hiestand PC, Mekler P, Nordmann R, Grieder A, Permmongkol C. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporin. Proc Natl Acad Sci USA 1986;83:2599-603.
17. fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes. Mol Endocrinol 1994;8:674-81.
18. Neidhart M. Prolactin in autoimmune diseases. Proc Soc Exp Biol Med 1998;217:408-19.
19. Berczi I. Prolactin, pregnancy and autoimmune disease. J Rheumatol 1993;20:1095-100.
20. Gagnerault M, Touraine P, Savino W, Kelly PA, Dardenne M. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. J Immunol 1993;150:5673-81.
21. Nagy E, Berczi I, Wren GE, Asa SL, Kovazs K. Immunomodulation by bromocriptine. Immunopharmacol 1983;6:231-43.
22. Gutierrez MA, Molina JF, Jara LJ, et al. Prolactin induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals. Int Arch Allergy Immunol 1996;109:229-35.
23. Blank M, Krause I, Buskila D, et al. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 1995;162:114-22.
24. McMurray RW, Allen SH, Braun AL, Rodriguez F, Walker SE. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease. J Rheumatol 1994;21:843-50.
25. Folomeev M, Prokaeva T, Nassonova V. Prolactin levels in men with SLE and RA [letter]. J Rheumatol 1993;17:1569-70.
26. Jara-Quezada L, Graef A, Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 1991;18:349-53.
27. Jara LJ, Gomez-Sanchez C, Silveiria LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus. Association with disease activity. Am J Med Sci 1992;303:222-6.
28. Ferrai C, Boghen M, Paracchi A, et al. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinol 1983;104:35-41.
29. Lever EG, McKerron CG. Autoimmune Addison's disease associated with hyperprolactinemia. Clin Endocrinol 1984;21:451-7.
30. Chikanza IC, Chrousos G, Panayi GS. Abnormal neuroendocrine immune communications in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22:635-7.
31. Jorgensen C, Sany J. Modulation of the immune responses by the neuro-endocrine axis in rheumatoid arthritis. Clin Exp Rheumatol 1994;12:435-41.
32. Jorgensen C, Maziad H, Bologna C, Sany J. Kinetics of prolactin release in rheumatoid arthritis. Clin Exp Rheumatol 1995;13:705-9.
33. Figueroa F, Carrion F, Martinez ME, Rivero S, Mamani I, Gonzalez G. Effect of bromocriptine in patients with active rheumatoid arthritis. Rev Med Chil 1998;126:33-41.
34. Whyte A, Williams RO. Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis. Arthritis Rheum 1988;31:927-8.
35. Berczi I, Nagy E, Asa SL, Kovacs K. The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum 1984;27:682-8.
36. Lavalle C. Prolactin - a hormone with immunoregulatory properties that leads to new therapeutic approaches in rheumatic diseases. J Rheumatol 1992;19:839-41.
37. Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994;37:808-13.
38. Brennan P, Ollier B, Worthington J, Hajeer A, Silman A. Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Lancet 1996;348:106-9.
39. Chikanza IC, Petrou P, Chrousos G, Kingsley G, Panayi G. Excessive and dysregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implications. Br J Rheumatol 1993;32:445-8.
40. McMurray RW, Allen SH, Pepmueller PH, Keisler D, Cassidy JT. Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. J Rheumatol 1995;22:1577-80.
41. Mattsson R, Mattsson A, Hansson I, Holmdahl R, Rook GA, Whyte A. Increased levels of prolactin during, but not after, the immunization with rat collagen II enhances the course of arthritis in DBA/1 mice. Autoimmunity 1992;18:349-53.
42. Kullich WC, Klein G. High levels of macrophage inflammatory protein-1 alpha correlate with prolactin in female patients with active rheumatoid arthritis. Clin Rheumatol 1998;17:263-4.
43. Parkes D. Drug therapy bromocriptine. N Engl J Med 1979;301:873-8.
44. Figueroa FE, Carrion F, Martinez ME, Rivero S, Mamani I, Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis [letter]. Br J Rheumatol 1997;36:1022-3.
45. Dougados M, Duchesne L, Amor B. Bromocriptine and cyclosporin A combination therapy in rheumatoid arthritis [letter]. Arthritis Rheum 1988;31:1333-4.
46. Panayi GS. Hormonal control of rheumatoid inflammation. Br Med Bull 1995;51:462-71.
47. Amett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
48. Wakisaka S, Suzuki N, Saito N, Ochi T, Sakane T. Possible correction of abnormal rheumatoid arthritis synovial cell function by jun D transfection in vitro. Arthritis Rheum 1998;41:470-81.
49. Sakane T, Murakawa Y, Takeno M, Shigeki T, Nagafuchi H, Miki T. T cell interactions in active rheumatoid arthritis: insights from the human autologous mixed lymphocyte reaction as a model of T cell activation cascade. Clin Exp Immunol 1991;85:55-60.
50. Gronblad M, Konttinen YT, Korkala O, Liesi P, Hukkanen M, Polak JM. Neuropeptides in synovium of patients with rheumatoid arthritis and osteoporosis. J Rheumatol 1988;15:1807-10.
51. Brenner CA, Tam AW, Nelson PA, et al. Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques 1989;7:1096-103.
52. Sabharwal P, Glaer R, Lafuse W, et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: An autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci USA 1992;89:7713-6.
53. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997;99:618-27.
54. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription inhibition by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl Acids Res 1983;11:1475-89.
55. Kobayashi T, Hattori S, Nagai Y, Sakuraoka K, Nishikawa T. Secretion of different types of gelatinases from cultured human keratinocytes. J Dermatol 1997;24:213-6.
56. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196-202.
57. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteases 1 in patients with rheumatoid arthritis: relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995;38:1031-9.
58. Okada Y, Nagase H, Harris ED Jr. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J Rheumatol 1987;14:41-2.
59. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;54:2145-54.
60. Gouilleux F, Moritz D, Humar M, Moriggl R, Berchtold S, Groner B. Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor. Endocrinol 1995;136:5700-8.
61. Ferrari C, Mattei A, Melis GB, et al. Cabergoline: long acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201-6.
62. Malone DG, Wahl SM, Tsokos M, Cattell H, Decker JL, Wilder RL. Immune function in severe, active rheumatoid arthritis. J Clin Invest 1984;74:1173-85.
63. Mui AL, Wakao H, Harada N, O'Farrell AM, Miyajima A. Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through 2 forms of STAT5. J Leukocyte Biol 1995;57:799-803.
64. Hide I, Toriu N, Nuibe T, et al. Suppression of TNF-α secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-α release, transcription, and degranulation. J Immunol 1997;159:2932-40.